Tesamorelin and cognition in HIV: what the 2025 trial reported
A 2025 Journal of Infectious Diseases paper asked whether a GHRH analog changes cognition in people with HIV and abdominal obesity.
Growth-hormone axis drugs are sometimes marketed as “nootropics.” A 2025 randomized study tested a more specific question: does tesamorelin change neurocognition in people with HIV and abdominal obesity?
Why this paper matters
It is one of the few recent controlled human papers on a GHRH analog that measures a brain-related outcome rather than only IGF-1 or waist circumference. The population is the same medical group tesamorelin was developed for, not healthy adults chasing anti-aging stacks.
How to read it
A single trial cannot settle whether GH-axis peptides improve memory in the general public. It can show whether, in a defined clinical group, cognition moved with the drug versus control — and what side-effect tradeoffs appeared. Always check whether the primary cognitive endpoint was prespecified and whether effects were large enough to matter to patients.
Bottom line
Evidence ladder: Human RCT in a specific HIV population. It is not evidence that research-chemical GHRH analogs improve cognition in healthy people.
Sources
Educational content only — not medical advice. See our Medical disclaimer and Editorial policy.